Identity
What is retatrutide?
Retatrutide is an investigational peptide agonist studied at GIP, GLP-1, and glucagon receptors. Its development code is LY3437943.
Peptide research reference
Retatrutide research reference
Retatrutide (LY3437943) is an investigational peptide studied at GLP-1, GIP and glucagon receptors. This reference explains its identity, receptor terminology and clinical research sources.
Published by Elevated Pharma ·
Research context
What the literature covers
The research includes a published randomized phase 2 trial, sponsor-reported phase 3 results and an ongoing registered comparison with tirzepatide. Each source has a different purpose and evidence status.
Evidence boundary
What the record does not establish
Clinical-trial results do not establish the identity, quality, safety, or permitted use of an independently sourced material.
U.S. context
Current research status
The cited records describe an investigational program. This library does not assert FDA-approved product status.
Reference identifiers
Retatrutide identity data
- Primary name
- Retatrutide
- Development code
- LY3437943
- Research class
- Triple-receptor peptide agonist
Receptor terminology
What does triple-receptor agonist mean?
An agonist activates a receptor. In the cited research, retatrutide is studied across three receptor systems. The names below identify those systems; they do not state a result for an independently supplied material.
- GLP-1 receptor
- The receptor for glucagon-like peptide-1.
- GIP receptor
- The receptor for glucose-dependent insulinotropic polypeptide.
- Glucagon receptor
- The third receptor target in retatrutide's research profile, also abbreviated GCGR.
- Primary reference
- Jastreboff and colleagues, NEJM, 2023.
Study status
Retatrutide and tirzepatide research
The substances have separate identities and study records. A comparison needs an exact trial, a defined comparator and a shared endpoint. Percentages from unrelated studies cannot establish a controlled head-to-head ranking.
See the tirzepatide research reference for its identity and sources.
- Registered comparison
- NCT06662383: retatrutide compared with tirzepatide.
- Registry status
- Active, not recruiting. The record was last updated July 20, 2026 and checked for this reference on September 9, 2026.
- Estimated primary completion
- November 2026, according to that registry update. This is an estimate, not a result or approval date.
- Interpretation
- The registration confirms that a comparison is being studied. It does not establish a completed comparative finding.
Reading the sources
Match the claim to the evidence
A paper, a registry and a sponsor announcement answer different questions. Check what was studied, how it was compared and which findings were actually reported before carrying a statement into another context.
- Published trial paper
- Read the methods, study population, comparator, endpoints and limitations together. The abstract is an entry point, not the complete analysis.
- Trial registry
- Use the dated record to identify the planned design and current recruitment or completion status. A registered study is not automatically a published result.
- Sponsor announcement
- Treat sponsor-reported findings as that source type. Check whether the full methods and analysis are available in a primary publication.
- Material identity
- Published research does not authenticate an independent batch. Read our source and material-evidence methodology for the separate roles of identity, specifications and lot documentation.
Primary sources
Retatrutide research references
- Phase 2 retatrutide trial PubMed
- Registered retatrutide–tirzepatide comparison NCT06662383 ClinicalTrials.gov · Updated July 20, 2026
- TRIUMPH-1 phase 3 presentation Lilly · Sponsor presentation · June 2026
- Sponsor overview of investigational retatrutide Lilly · Sponsor information
Research questions
Retatrutide names, studies and evidence
What does Reta mean on this site?
Reta is shorthand used in our editorial content for Retatrutide. LY3437943 is the development code in the cited study records. Use the full name and source identifier when matching a research record.
Is LY3437943 the same research identity as retatrutide?
Yes. The cited primary paper and clinical-study record identify Retatrutide by the development code LY3437943. A supplier code or package label still requires its own identity verification.
Is there a retatrutide versus tirzepatide study?
Yes. NCT06662383 is a registered comparison. The July 20, 2026 registry update lists it as active, not recruiting, with estimated primary completion in November 2026. This page does not assert a completed head-to-head result.
Why are three receptor names listed?
Retatrutide is studied as an agonist at GLP-1, GIP and glucagon receptors. These are the receptor systems described in the cited research; the list is not a promise of an outcome.
Does the literature verify a laboratory lot?
No. A reference paper describes its study material and protocol. An independently supplied batch needs matching identity, analytical and chain-of-custody records. Use exact lot documentation and an approved institutional protocol for laboratory handling.